BMS Appoints Oncology Development Head

Fouad Namouni, M.D., has been appointed Oncology Development Head, Bristol-Myers Squibb, responsible for leading a comprehensive development strategy for the company’s oncology pipeline from early development through commercialization. He will continue to report to Francis Cuss, MB Bchir, FRCP, executive vice president, chief scientific officer, and remain a member of the R&D Leadership Team.

Most recently, Dr. Namouni served as head of Medical, leading the worldwide medical organization and prior to that, was the development lead for Yervoy and Opdivo. Dr. Namouni joined Bristol-Myers Squibb in France in 1999 as life-cycle manager for Taxol and has held positions of increasing responsibility in R&D since.    

“Fouad has demonstrated highly successful strategic and visionary leadership in oncology and immuno-oncology drug development and medical affairs throughout his career at Bristol-Myers Squibb,” said Mr. Cuss. “As a trained pediatric oncologist, Fouad brings to this role exceptional clinical experience and an unwavering commitment to patients. I am confident that our oncology development programs will continue to thrive under his leadership.”